ClinicalTrials.gg
RecruitingNCT05779735DELIVERYUpdated Feb 15, 2024

Validation of Ultrasound "Angle of Progression" Measurement to Decrease the Cesarean Rate

An interventional study of Transperineal ultrasound measurements of AOP in Prolonged Second Stage of Labor, sponsored by Hospital St. Joseph, Marseille, France. Recruiting at 7 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-15.

Sponsored by Hospital St. Joseph, Marseille, France · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Sep 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Ultrasound during labor and measurement of Angle of progression showed extensive prospective and retrospective publications since 2010. The investigators performed between 2013 and 2016 the only one multicenter, randomized controlled Trial comparing digital exam to angle of progression after a prolonged 2-hour second stage of labor with uncertain fetal head. The investigators consider a cut off of 120° to accepted vaginal birth among cephalic occiput anterior position This randomised PILOT study showed that measurement of Angle of progression in addition to digital exam reduced caesarean delivery from 41% to12% ( n= 33, p=0,06). doi: 10.1016/j.ajog.2022.04.018.

The objective of this new study is therefore to validate the results of this PILOT study in a more powerful multicenter randomized trial (DELIVERY).

02

Conditions studied

  • Prolonged Second Stage of Labor

Keywords

  • angle of progression
  • cesarean delivery
  • transperineal ultrasound
03

In context

Lead sponsor

Hospital St. Joseph, Marseille, France is the lead sponsor of 31 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Nulliparous or multiparous women with no history of vaginal delivery,
  • > or = 37 weeks amenorrhoea
  • Cephalic presentation in anterior position (occipito-pubic position, left anterior occipito-iliac and right anterior occipito-iliac ) confirmed by ultrasound
  • uncertain fetal head engagement on digital examination or midline fetal presentation in prolonged second stage of labor (at least 2 hours),

Exclusion criteria

Exclusion Criteria:

  • Multiparous women who were previous vaginal deliveries,
  • Presentation other than cephalic,
  • Twin pregnancies,
  • Posterior or transverse position
  • Transperineal ultrasound for head-perineum distance measurement
  • Fetal heart rate abnormalities requiring rapid delivery,
  • to vaginal delivery whether maternal or fetal
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (estimated)

Study arms

  • No intervention
    Group 1 : control

    The mode of delivery will be determined by clinical examens (digital examination)

  • Experimental
    Group 2 : Transperineal ultrasound measurements of AOP

    The mode of delivery will be determined by clinical examens (digital examination) and ultrasound measurement of the AOP : * vaginal delivery is encouraged if AOP measurement is \>120° * cesarean delivery is encouraged if AOP measurement is \<= 120°

    Diagnostic Test: Transperineal ultrasound measurements of AOP

Interventions

  • Diagnostic testTransperineal ultrasound measurements of AOP

    The angle of progression (AOP) defined as the angle between the pubic bone axis and the leading part of the fetal head

06

What researchers measure

Primary outcomes

  1. cesarean delivery rate

    Demonstrate that the angle of progression measurement would change by 20% the cesarean rate after a prolonged second stage of labor (2 hours).

    Time frame: baseline

Secondary outcomes

  1. Number of complicated deliveries in each group

    A complicated deliveries is defined by the occurrence of at least one of the following events : * Failed instrumental extraction * Sequential use of a second instrument, * Difficult instrumental extraction defined as : * vacuum detachment * requires the use of a second instrument, * extraction time \> 10 minutes, * operator's impression of the difficulty of extraction, * Shoulder dystocia by obstetric maneuver

    Time frame: baseline

  2. Severe maternal morbidity, in each group

    Severe maternal morbidity is defined by the occurrence of at least one of the following events: * postpartum hemorrhage requiring hysterectomy, embolization, conservative surgical treatment or blood transfusion, * third or fourth degree perineal tears * vaginal thrombus, * cervical tear, * surgical wounds * sepsis, amniotic embolism, cardiac complication or renal failure.

    Time frame: 1 month

  3. Severe neonatal morbidity, in each group

    Severe neonatal morbidity, in each group, defined by the occurrence of at least one event below: * severe biological signs * moderate or absent biological signs but associated with perinatal events * seizure * severe neonatal trauma * Fetal death or neonatal death.

    Time frame: 1 month

  4. Rate of admission to neonatal intensive care unit, in each group

    Number of newborns admitted to intensive care out of the total number of newborns

    Time frame: 1 month

  5. Concordance rate between the routinely AOP measurement and the centralized AOP measurement reading

    Centralized blind AOP measurement reading

    Time frame: 1 month

07

Study locations

7 of 7 sites recruiting
  • CHU de Lille - Hôpital Jeanne de Flandre
    Lille, 59000, France
    Recruiting
    • Charles GARABEDIAN · Principal investigator
  • APHM Hôpital Conception
    Marseille, 13005, France
    Recruiting
    • Florence Bretelle · Principal investigator
  • Hopital Saint Joseph
    Marseille, 13008, France
    Recruiting
    • Rahamia AHAMADA · Contact
    • Jean-Baptiste Haumonte · Principal investigator
  • APHM Hôpital Nord
    Marseille, 13015, France
    Recruiting
    • Pierre Castel · Principal investigator
  • Hôpital Armand Trousseau AP-HP
    Paris, 75012, France
    Recruiting
    • Anne PINTON · Principal investigator
  • CHIC Poissy
    Poissy, 78300, France
    Recruiting
    • Thibaud QUIBEL · Principal investigator
  • CHITS Hôpital Sainte Musse
    Toulon, 83000, France
    Recruiting
    • Franck MAUVIEL · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2023 (actual). Primary completion is estimated for Sep 2025, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2023
First posted
Mar 22, 2023
StartActual
Sep 13, 2023
Primary completionEst.
Sep 13, 2025
CompletionEst.
Oct 13, 2025
Last update
Feb 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05779735
Lead sponsor
Hospital St. Joseph, Marseille, France
Responsible party
Sponsor
First posted
Mar 22, 2023
Start date
Sep 13, 2023
Primary completion
Sep 13, 2025 (estimated)
Completion
Oct 13, 2025 (estimated)
Last update
Feb 15, 2024

Study contacts

Rahamia Ahamada
Contact
rahamada@hopital-saint-joseph.fr
0033488731071
Jean-Baptiste Haumonte
principal investigator · Hopital Saint Joseph Marseille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion